Rafael (NYSE:RFL – Get Free Report) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

11.3% of Rafael shares are owned by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. 32.9% of Rafael shares are owned by company insiders. Comparatively, 1.7% of 60 Degrees Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

This table compares Rafael and 60 Degrees Pharmaceuticals’ net margins, return on equity and return on assets.

This is a breakdown of recent ratings and recommmendations for Rafael and 60 Degrees Pharmaceuticals, as reported by MarketBeat.com.

60 Degrees Pharmaceuticals has a consensus target price of $17.60, indicating a potential upside of 502.74%. Given 60 Degrees Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than Rafael.

Rafael has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.92, meaning that its share price is 192% more volatile than the S&P 500.

This table compares Rafael and 60 Degrees Pharmaceuticals”s revenue, earnings per share and valuation.

60 Degrees Pharmaceuticals has lower revenue, but higher earnings than Rafael. Rafael is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

60 Degrees Pharmaceuticals beats Rafael on 8 of the 14 factors compared between the two stocks.

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.